Document Detail


A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
MedLine Citation:
PMID:  22278730     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: There is as yet no optimal treatment regimen for patients with epidermal growth factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has progressed despite cytotoxic chemotherapy. This trial was performed to evaluate the efficacy and toxicity of erlotinib, a tyrosine kinase inhibitor of EGFR, in Japanese patients with EGFR wild-type tumors.
METHODS: Patients with stage III/IV or postoperative recurrence of NSCLC whose tumors have wild-type EGFR were eligible. Erlotinib (150 mg/day) was administered until disease progression or unacceptable toxicity occurred. The primary end point was disease control rate (DCR).
RESULTS: Thirty-one patients (23 men and 8 women; median age, 71 years; range, 31-89) were enrolled between January 2008 and June 2011. Twenty-one had adenocarcinoma, nine had squamous cell carcinoma, and one had large cell carcinoma. Ten, nine, eight, and four patients showed performance status 0, 1, 2, and 3, respectively. Erlotinib was administered following the median 3.1 regimens of cytotoxic chemotherapies. One patient achieved complete response, four showed partial response, and eight had stable disease. Thus, response rate was 17.2%, and DCR was 44.8%. Skin rash was the most common side effect (80.6%). Two patients developed interstitial lung disease. Nevertheless, all of these events were reversible, and there were no treatment-related deaths. The median progression-free survival and survival times were 2.1 and 7.7 months, respectively.
CONCLUSION: Erlotinib might be an alternative option for patients resistant to cytotoxic chemotherapy even in those with EGFR wild-type NSCLC.
Authors:
Takashi Kobayashi; Tomonobu Koizumi; Toshihide Agatsuma; Masanori Yasuo; Kenji Tsushima; Keishi Kubo; Seiichiro Eda; Hiroshi Kuraishi; Shigeru Koyama; Tsutomu Hachiya; Nariaki Ohura
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article     Date:  2012-01-26
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  69     ISSN:  1432-0843     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-26     Completed Date:  2012-06-18     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1241-6     Citation Subset:  IM    
Affiliation:
Comprehensive Cancer Center, Division of Clinical Oncology, Shinshu University School of Medicine, Shinshu University Hospital, 3-1-1, Asahi Matsumoto, Matsumoto 390-8621, Japan. tomonobu@shinshu-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy,  pathology
Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung / drug therapy*,  pathology
Carcinoma, Squamous Cell / drug therapy,  pathology
Disease-Free Survival
Female
Humans
Japan
Lung Neoplasms / drug therapy*,  pathology
Male
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Prospective Studies
Protein Kinase Inhibitors / adverse effects,  pharmacology,  therapeutic use*
Quinazolines / adverse effects,  pharmacology,  therapeutic use*
Receptor, Epidermal Growth Factor / antagonists & inhibitors*
Survival Rate
Treatment Outcome
Chemical
Reg. No./Substance:
0/Protein Kinase Inhibitors; 0/Quinazolines; EC 2.7.10.1/Receptor, Epidermal Growth Factor; J4T82NDH7E/erlotinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vitro determination of anticryptosporidial activity of phytogenic extracts and compounds.
Next Document:  Prognostic significance of MRP5 immunohistochemical expression in glioblastoma.